Drugs in MeSH Category Anti-Inflammatory Agents, Non-Steroidal

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal Pharms	IBUPROFEN	ibuprofen	CAPSULE;ORAL	202300-001	Dec 23, 2011		OTC	No	No
Padagis Us	IBUPROFEN	ibuprofen	SUSPENSION;ORAL	076925-001	Sep 23, 2004	AB	RX	No	No
Watson Labs	IBUPROFEN	ibuprofen	TABLET;ORAL	071547-001	Jul 2, 1987		DISCN	No	No
Alcon Labs Inc	PATADAY TWICE DAILY RELIEF	olopatadine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	020688-001	Dec 18, 1996		OTC	Yes	Yes
Chartwell Molecules	INDOMETHACIN	indomethacin	CAPSULE;ORAL	018829-001	Aug 6, 1984	AB	RX	No	No
Gland	OLOPATADINE HYDROCHLORIDE	olopatadine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	209752-001	May 20, 2020		OTC	No	No
Pfizer	AZULFIDINE	sulfasalazine	TABLET;ORAL	007073-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes

Market dynamics and patent landscape for drugs in NLM MeSH Class: Anti-Inflammatory Agents, Non-Steroidal

Last updated: April 24, 2026

How big is the non-steroidal anti-inflammatory drug (NSAID) opportunity by mechanism and use?

NSAIDs sit in the intersection of chronic pain, musculoskeletal inflammation, fever, and acute pain. In practical commercial terms, the market dynamics split across two axes:

1) COX inhibition profile

• COX-2 selective: celecoxib (and older branded predecessors in some markets) competes for patients needing lower gastrointestinal (GI) risk.
• Nonselective COX inhibitors: ibuprofen, naproxen, diclofenac, indomethacin and others dominate volume where payer rules and OTC access shape uptake.
• Prodrug and combination strategies: products such as topical diclofenac formulations and other derivative strategies are used to reduce systemic exposure while preserving localized efficacy.

2) Route of administration

• Oral drives the largest share for chronic conditions (osteoarthritis, rheumatoid arthritis, ankylosing spondylitis) but faces intense generic price pressure.
• Topical captures localized osteoarthritis and offers differentiation for GI and systemic tolerability constraints.

In the patent landscape, the core commercial reality is that many oral NSAIDs are off-patent, and new IP primarily concentrates in formulation, combinations, dosing regimens, and anti-inflammatory targeting approaches rather than first-principles COX inhibitor novelty.

What do payer and channel dynamics do to pricing and patent value?

NSAIDs experience:

• High generic penetration in oral space (liberating competitors once core patents expire).
• OTC-to-prescription channel switching in many geographies for ibuprofen and naproxen, reducing branded lifecycle runway.
• Formulation-led differentiation to sustain exclusivity at the margins (topical delivery, controlled release, patch or gel formats).

These dynamics pressure the patent strategy:

• Strongest monetization tends to come from patents tied to non-interchangeable product formats or new molecular entities with meaningful differentiation.
• Weakest monetization comes from “me too” improvements that do not establish clear clinical advantages over existing generics.

Which therapeutic areas drive demand most reliably for NSAIDs?

Across typical regulatory and clinical usage patterns, NSAIDs map most consistently to:

• Osteoarthritis
• Rheumatoid arthritis and other inflammatory arthritides
• Ankylosing spondylitis
• Acute musculoskeletal pain
• Dysmenorrhea and fever (less IP-intensive due to generic dominance)

The MeSH category itself identifies the broad drug class framing for these indications, but commercial differentiation comes from individual product positioning (selectivity, route, tolerability, and safety labeling) rather than category membership. The class definition is anchored in NLM indexing under Anti-Inflammatory Agents, Non-Steroidal. [1]

---

Patent landscape: where the IP still is (and where it is gone)

What is the patent “life pattern” for NSAIDs?

For NSAIDs as a class, patent timelines typically follow a mature lifecycle:

• Late-stage innovation shifts from new COX inhibitors to product optimization once major oral molecules mature.
• Therapeutic differentiation concentrates on safety and delivery (GI risk mitigation, topical exposure, reduced systemic side effects).
• Combination strategies and specific patient subgroups become more common where label expands.

This creates a landscape where:

• Molecules (old COX inhibitors) are largely generic.
• Product form and use-specific IP remain the most actionable segments for new entrants and investors.

Where do patents concentrate inside the MeSH class?

In practice, patent filings in NSAIDs cluster in these buckets:

• New formulations: topical gels, solutions, patches, extended release, and controlled exposure systems.
• New dosing regimens: titration schedules, intermittent use, or concentration-specific regimens tied to efficacy/safety claims.
• Use patents: new indications, patient populations, or comorbidity-driven claims (for example, GI risk stratification).
• Combination products: co-formulations or fixed-dose combinations where patent protection attaches to the specific pairing and regimen.

The NLM MeSH class provides drug-class grouping rather than IP segmentation; IP segmentation is derived from the patent strategy pattern seen across NSAID product development and lifecycle management. [1]

What does this mean for competitive entry timing?

For an R&D or investment screen, the practical inference is:

• Oral systemic NSAID development faces a high hurdle: core IP is mostly expired; differentiation must be clinical and not simply incremental.
• Topical and delivery-technology development remains fertile: product format can be protected even when the underlying drug is off-patent.
• Safety-anchored differentiation works best when it ties to a labeling endpoint that can be defended with data.

---

Market and patent interaction: strategic implications by drug type

Are COX-2 selective NSAIDs under tighter IP pressure or better positioned?

COX-2 selective agents have historically maintained stronger differentiation around GI tolerability compared with nonselective NSAIDs. In the current landscape, however, most major COX-2 selective molecules are off-patent in many jurisdictions, which shifts value capture toward:

• Brand-specific remaining lifecycle assets (if any)
• Formulation variants
• Use-expansion strategies (where new clinical or label language supports additional exclusivity)

In IP terms, the selective-COX signal often functions as a label and sales advantage rather than a permanent barrier to generic substitution once the core compound patents end.

How does topical delivery change the patent and market equation?

Topical NSAIDs:

• Reduce systemic exposure, improving tolerability for many users
• Expand the addressable segment in osteoarthritis and localized pain
• Offer more defensible product differentiation via formulation patents

This is where the market dynamics favor brand survival even with mature active ingredients: delivery systems and dosing design are patentable, and interchangeability is lower than for oral generics because specific formulations are not always substitutable under real-world pharmacy and payer rules.

Where do combination strategies fit in the NSAID patent landscape?

Combination products attempt to extend monetization by patenting:

• Specific fixed-dose combinations
• Specific ratios or release profiles
• Specific regimens tied to safety and tolerability

Combination strategies also interact with payer formularies: when a combination is positioned to reduce overall medication burden, it can gain placement even when each ingredient is individually generic. IP value rests on whether the combination and regimen are protected and whether payers treat the product as a distinct therapeutic option.

---

Mapping the MeSH class to defensible IP categories for business screens

What are the highest-ROI IP targets for NSAID programs under this class?

For programs mapped to Anti-Inflammatory Agents, Non-Steroidal, the highest defensibility typically attaches to:

1) Dose-form and delivery IP

• Topical formulations and controlled release systems
• Bioavailability modulation systems

2) Regimen and patient-constraint IP

• Use claims that align to subgroup labeling and outcomes
• Safety-driven use claims (GI risk stratification, comorbidity-driven endpoints)

3) Product-specific combination IP

• Fixed-dose combinations with protected ratios and release features
• Co-therapy regimens anchored to clinical endpoint claims

This is the operational side of how NSAID development stays patent-relevant after compound patents expire. [1]

What are the lowest-ROI IP targets under this class?

The lowest ROI areas generally include:

• Minor polymorph changes without meaningful product performance differentiation
• Broad use claims that do not translate into enforceable, label-consistent outcomes
• “Skin-deep” method-of-use patents without a product that is commercially non-substitutable

These tend to lose value under generic substitution and payer interchangeability.

---

Key Takeaways

• The NSAID market is mature in oral systemic space, pushing differentiation toward topical and delivery-formulation, regimen, use-specific label claims, and combination strategies.
• The patent landscape in this MeSH class follows lifecycle gravity: molecules are mostly off-patent, while product format and delivery remain the most actionable IP levers.
• Business value in NSAIDs is less about discovering another COX inhibitor and more about protecting non-interchangeable product differentiation that can survive payer substitution pressure.
• Under the MeSH grouping Anti-Inflammatory Agents, Non-Steroidal, the practical competitive map is structured by route (oral vs topical) and by tolerability positioning (COX-2 selective vs nonselective vs formulation-constrained exposure).

---

FAQs

1) Does the MeSH class “Anti-Inflammatory Agents, Non-Steroidal” imply a single mechanism or a single patent strategy?

No. The class groups multiple NSAIDs with different COX profiles and multiple delivery approaches. Patent strategy typically shifts from compound-level IP to formulation and use-based IP as molecules age. [1]

2) What is the main reason oral NSAID brand value erodes faster than topical?

Oral NSAIDs face high generic interchangeability and frequent OTC availability, compressing price and reducing the commercial value of remaining compound-level exclusivity. Topical products can preserve non-interchangeable differentiation through formulation and localized dosing. [1]

3) Are COX-2 selective NSAIDs easier to protect than nonselective NSAIDs?

Not in the long-run. COX selectivity can support tolerability positioning, but patent value depends on remaining exclusivity for the compound and on whether the product is protected beyond the active ingredient via formulation or use. [1]

4) Which NSAID-related patent categories most often survive generic substitution pressures?

Patents tied to formulation/delivery, protected regimen specifics, and combination product identity generally survive substitution better than broad compound-only claims in mature molecules. [1]

5) How should an investor time entry into an NSAID program under this MeSH scope?

Entry timing favors moments when a product has defensible, non-interchangeable differentiation (topical delivery, controlled release, protected regimen, or combination-specific IP) rather than relying on compound novelty in a class with widespread generic availability. [1]

---

References

[1] National Library of Medicine. MeSH: Anti-Inflammatory Agents, Non-Steroidal. U.S. National Library of Medicine. https://www.nlm.nih.gov/mesh/